Serum non-high-density lipoprotein cholesterol is associated with the risk of sudden sensorineural hearing loss

Saibin Wang, MD\textsuperscript{a,*}, Qian Ye, MD\textsuperscript{b}, Yibin Pan, MD\textsuperscript{c,*}

Abstract

The aim of this study was to investigate the association between the non-high-density lipoprotein cholesterol (non-HDL-C) with sudden sensorineural hearing loss (SSHL) and the predictive value of non-HDL-C for SSHL.

A total of 324 patients with SSHL and 972 well-matched controls were enrolled from 2009 to 2012 in Korea. The association of serum non-HDL-C with the risk of SSHL was evaluated using multivariate regression analysis, smooth curve fitting after adjusting for potential confounders. The discrimination ability of non-HDL-C in predicting SSHL was determined by calculating the area under the curve (AUC), and its clinical usefulness was evaluated by decision curve analysis. This was a secondary analysis of a case–control study.

There was a non-linear relationship between the serum non-HDL-C and the incidence of SSHL. After adjustment for potential confounders, the incidence of SSHL rose significantly with ascending quartiles of serum non-HDL-C (using Q1 as the reference group, the OR [95% CI] of Q2, Q3, and Q4 were 4.34 [2.43–7.74], 7.08 [3.99–12.56], and 20.88 [11.86–36.75], respectively [P for trend < .0001]). The discrimination ability of serum non-HDL-C in predicting SSHL was 0.747 (95% CI, 0.717–0.776), and the AUC was 0.733 (95% CI, 0.705–0.777) in the internal validation.

Elevated serum non-HDL-C was strongly associated with increased risk of SSHL, and it may play a role as a useful biomarker in predicting the risk of SSHL.

Abbreviations: AUC = area under the curve, BMI = body mass index, CHD = coronary heart disease, CI = confidence interval, CRF = chronic renal failure, CVD = cardiovascular disease, DCA = decision curve analysis, DM = diabetes mellitus, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, OR = odds ratio, SSHL = sudden sensorineural hearing loss, TC = total cholesterol, TG = triglycerides.

Keywords: lipid, non-high-density lipoprotein cholesterol, prediction, sudden sensorineural hearing loss

1. Introduction

As an audiologic emergency disease, sudden sensorineural hearing loss (SSHL) is characterized by a rapid decline in hearing.[1] According to clinical practice guideline, SSHL is defined as sudden hearing loss of more than 30dB measured over at least three consecutive frequencies of pure tone audiometry and maintaining for at least 24h.\textsuperscript{2} The estimated prevalence of SSHL ranges from 5 to 30 cases per 100,000 people a year, and it has a higher prevalence in unilateral SSHL than in bilateral SSHL.\textsuperscript{3,4} Notably, ~40% to 70% of the SSHL patients fail to recover within 2 weeks,\textsuperscript{5} and 13% of those who exhibit spontaneous recovery will inevitably experience recurrent episode of SSHL.\textsuperscript{6,7}

The underlying pathogenesis of SSHL, however, has not been fully elaborated. Reportedly, autoimmune diseases, blood vessel disorders, and viral infections may be related to developing SSHL.\textsuperscript{3,8,9} Nevertheless, for the majority of patients with SSHL, the etiology is still unclear, which is namely idiopathic SSHL. In the last few decades, several studies have reported that there is an association between lipid profiles and risk of SSHL.\textsuperscript{3,10,11} Generally, the cochlea is supplied by one to several terminal arteries with no collateral circulation. The current explanation for the “lipid hypothesis” is that elevated blood lipid increases blood viscosity and contributes to atherosclerosis of the vessels supplying to the cochlea, and thus may result in hearing impairment.\textsuperscript{12} In contrast, as a multi-components lipid parameter, the non-high-density lipoprotein cholesterol (non-HDL-C) has showed great value in predicting the risk for...
cardiovascular disease (CVD). Therefore, we made a hypothesis that the non-HDL-C associates with the risk of SSHL and has potential to predict SSHL. In this study, we investigated the specific association between the non-HDL-C with the risk of SSHL and the predictive value of non-HDL-C for SSHL was also analyzed based on a case-control study.

2. Materials and methods

2.1. Study design and ethics statement

This was a secondary analysis of a large-scale case-control study. A total of 324 patients with unilateral SSHL were consecutively collected at a University-affiliated hospital in Korea between 2009 and 2012, and 972 well-matched participants were collected from the Korea National Health and Nutrition Examination Survey (KNHANES) as controls (three controls per case) between 2009 and 2010. In the previously published article, Lee et al. have clearly stated that the study was approved by the Institutional Review Board of Hallym University Sacred Heart Hospital. Verbal informed consent was obtained from all participants after being fully informed of the pertinent study information (purpose, procedures, potential benefits, and alternatives to participation).

The following details were collected: gender, age, weight, body mass index (BMI), coexisting diseases (hypertension, diabetes mellitus [DM], stroke, coronary heart disease [CHD], and chronic renal failure [CRF]). Blood lipid variables included total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-DL-C (LDL-C), and non-HDL-C (calculated as subtracting HDL-C from TC). Blood lipid profiles were measured between 6 and 8 AM in all the participants after an overnight fast. All the patients with SSHL in the present study were unilateral SSHL and fulfilled the audiometric criterion of SSHL.

2.2. Statistical analyses

Descriptive statistics were used to summarize baseline characteristics and blood lipid profiles. Continuous data were presented as mean ± standard deviation, and categorical data were expressed as the number and the percentage. Unpaired t test or Kruskal-Wallis rank sum test, Pearson chi-squared test or the Fisher exact test was performed between the SSHL group and the non-SSHL group (Table 1). However, the blood lipid profiles (TG, TC, HDL-C, and non-HDL-C) were significantly higher in the SSHL group than in the non-SSHL group (Table 2, P < .05). Moreover, DM, CRF, and BMI were found to be positively correlated with SSHL as assessed by univariate analysis (Table 2, P < .05).

During the process of screening variables that need to be adjusted, variables of weight, TC, and HDL-C were removed from multicollinearity test. Variables of DM, CRF, and BMI were selected based on the criterion of adjust I, while age and gender were also adjusted according to the criterion of adjust II. A non-linear relationship was observed between the non-HDL-C and the risk of SSHL in smooth curve fitting after adjusting for confounders based on adjust II (including DM, CRF, BMI age, and gender) (Fig. 1). Both in the unadjusted model and in the adjusted models, the incidence of SSHL increased significantly with increasing concentration of serum non-HDL-C (Table 3). In multivariate regression analysis, using Q1 as the reference group, the OR (95% CI) of Q2, Q3, and Q4 of serum non-HDL-C were 4.34 (2.43–7.74), 7.08 (3.99–12.56), and 20.88 (11.86–36.75), respectively (P for trend <.0001) after adjusting for the potential confounders (Table 3, adjust II).

3. Results

In the present study, a total of 324 SSHL patients and 972 controls with normal hearing were recruited. No significant difference in participant demographic characteristics was observed between the SSHL group and the non-SSHL group (Table 1). However, the blood lipid profiles (TG, TC, HDL-C, and non-HDL-C) were significantly higher in the SSHL group than in the non-SSHL group (Table 2, P < .05). Moreover, DM, CRF, and BMI were found to be positively correlated with SSHL as assessed by univariate analysis (Table 2, P < .05).

![Table 1: Baseline characteristics and blood lipid profiles of the participants.](image)

| Variables | Participants with SSHL |  |  |
|---|---|---|---|
| Age (year) | 49.6 ± 16.5 | 48.8 ± 14.7 |
| Gender, n (%) |  |  |
| Male | 162 (50.0) | 452 (46.5) |
| Female | 162 (50.0) | 520 (53.5) |
| BMI (kg/m²) | 23.9 ± 3.3 | 23.3 ± 3.2 |
| Weight (kg) | 63.8 ± 11.6 | 61.7 ± 11.1 |
| Coexisting diseases |  |  |
| Hypertension, n (%) |  |  |
| No | 253 (78.09) | 797 (82.00) |
| Yes | 71 (21.91) | 175 (18.00) |
| DM, n (%) |  |  |
| No | 263 (87.35) | 886 (91.15) |
| Yes | 41 (12.65) | 86 (8.85) |
| CHD, n (%) |  |  |
| No | 318 (98.15) | 955 (98.25) |
| Yes | 6 (1.85) | 17 (1.75) |
| CRF, n (%) |  |  |
| No | 318 (98.15) | 971 (99.90) |
| Yes | 6 (1.85) | 1 (0.10) |
| Stroke, n (%) |  |  |
| No | 316 (97.53) | 959 (98.66) |
| Yes | 8 (2.47) | 13 (1.34) |
| Blood lipids |  |  |
| TG (mg/dL) | 122.8 ± 77.2 | 109.6 ± 65.3 |
| TC (mg/dL) | 192.8 ± 32.9 | 182.5 ± 34.9 |
| HDL-C (mg/dL) | 57.6 ± 15.3 | 54.3 ± 13.0 |
| LDL-C (mg/dL) | 110.7 ± 35.6 | 107.2 ± 31.2 |
| Non-HDL-C (mg/dL) | 160.5 ± 35.9 | 129.1 ± 33.1 |

BMI = body mass index, CHD = coronary heart disease, CRF = chronic renal failure, DM = diabetes mellitus, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, SSHL = sudden sensorineural hearing loss, TC = total cholesterol, TG = triglycerides.
Table 2

Univariate analysis of possible influencing factors of the risk of SSHL.

| Variables          | Statistics | Developing SSHL |
|--------------------|------------|-----------------|
| Age (year)         | 49.0 ± 15.2| 1.00 (1.00, 1.01) 0.3803 |
| Gender, n (%)      |            |                 |
| Male               | 614 (47.4) | Ref.            |
| Female             | 682 (52.6) | Ref.            |
| BMI (kg/m²)        | 23.5 ± 3.2 | 0.87 (0.68, 1.12) 0.2750 |
| Weight (kg)        | 62.2 ± 11.3| 1.02 (1.01, 1.03) 0.0014 |
| Hypertension, n (%)|            |                 |
| No                 | 1050 (81.0)| 1.28 (0.94, 1.74) 0.1208 |
| Yes                | 246 (19.0) | Ref.            |
| DM, n (%)          |            |                 |
| No                 | 1169 (90.0)| 1.49 (1.01, 2.22) 0.0471 |
| Yes                | 127 (9.8)  | Ref.            |
| CHD, n (%)         |            |                 |
| No                 | 1273 (98.2)| 1.06 (0.41, 2.71) 0.9033 |
| Yes                | 23 (1.8)   | Ref.            |
| CRF, n (%)         |            |                 |
| No                 | 1289 (99.5)| 18.32 (2.20, 152.76) 0.0072 |
| Yes                | 7 (0.5)    | Ref.            |
| Stroke, n (%)      |            |                 |
| No                 | 1275 (98.4)| 1.87 (0.77, 4.55) 0.1689 |
| Yes                | 21 (1.6)   | Ref.            |
| TG (mg/dl)         | 112.9 ± 68.7| 1.00 (1.00, 1.03) 0.0033 |
| TC (mg/dl)         | 192.1 ± 39.0| 1.02 (1.01, 1.03) <0.0001 |
| HDL-C (mg/dl)      | 55.2 ± 13.7| 1.02 (1.01, 1.03) <0.0001 |
| LDL-C (mg/dl)      | 108.1 ± 32.4| 1.00 (1.01, 1.01) 0.0005 |
| Non-HDL-C (mg/dl)  | 137.0 ± 36.5| 1.03 (1.02, 1.03) <0.0001 |

BMI=body mass index, CHD=coronary heart disease, DM=diabetes mellitus, HDL-C=high density lipoprotein cholesterol, LDL-C=low density lipoprotein cholesterol, SSHL=sudden sensorineural hearing loss, TC=total cholesterol, TG=triglycerides.

4. Discussion

The present study showed that elevated serum non-HDL-C level is associated with increased risk of SSHL. Furthermore, our results revealed that serum non-HDL-C has the potential to be a useful biomarker in predicting the risk of SSHL.

Nowadays, due to the dilemmas in the field of prevention and treatment, SSHL remains a huge clinical and public healthcare challenge.[11] Despite several etiological risk factors have been proposed (e.g., autoimmune diseases, vascular diseases, and viral infection), most patients with SSHL could not be contributed to a clear etiology, and therefore they may experience ineffective treatment or recurrent episode of SSHL.[3,8,9] In the last few decades, based on the theory that abnormal blood supply of the cochlea may contribute to hearing impairment and blood viscosity could be affected by blood lipid concentration,[12] “lipid hypothesis” has been proposed by a number of studies.[3,10,11] Therefore, SSHL, at least to some extent, may represent the disorder metabolism of lipids. In a cohort study,
Ballesteros et al.\cite{10} reported that lipid profile positively correlated with the development of SSHL. Similarly, in a case–control study, Aimoni et al.\cite{3} pointed out that hypercholesterolemia was strongly associated with the risk of SSHL. Moreover, Lee et al.\cite{11} demonstrated that TG and TC were associated with the prevalence of SSHL and the prognosis of SSHL.

Non-HDL-C is calculated by subtracting HDL-C from TC,\cite{15} namely that it mainly contains TG, LDL-C, very-LDL-C, and intermediate-DL-C, and chylomicron remnants.\cite{16,17} Recently, non-HDL-C has been recommended as an important target in patients with CVD in the revised National Cholesterol Education Program guidelines.\cite{13} In addition, several prospective cohort studies have revealed that non-HDL-C is an independent risk factor for mortality in individuals free of CVD.\cite{18} Moreover, with the advantage of maintaining relative stability regardless of whether it is tested on a non-fasting status or not, Non-HDL-C will be more convenient in application than LDL-C and TG.\cite{19}

In the present study, we found that elevated serum non-HDL-C level was strongly associated with an increased incidence of SSHL. After adjusting for potential confounding risk factors (gender, age, DM, CRF, and BMI), the strength of this association did not change. It seems that when serum non-HDL-C level exceeds 250mg/dL, the risk of SSHL declines (Fig. 1); however, no statistically significant differences were observed for this trend. Only 8 cases of serum non-HDL-C level was >250mg/dL in this study population, which may affect the curve fitting in Figure 1. Furthermore, we analyzed the predictive role of serum non-HDL-C for SSHL. Although the discrimination ability of serum non-HDL-C in predicting SSHL was moderate (AUC: 0.747), non-HDL-C showed a good accuracy (75.08%) and specificity (82.20%). We also constructed a nomogram to quantify the risk of SSHL based on serum non-HDL-C concentration, which is easy to use and its clinical usefulness was supported by DCA. DCA is a novel method, which can offer insight into clinical consequences on the basis of threshold probability, and the net benefit could be derived from DCA.\cite{20,21}

Specifically, the DCA showed that if the threshold probability of an individual is <60%, using the nomogram based on serum non-HDL-C in the present study to predict SSHL will add more benefit than either the treat-all strategy or the treat-none strategy. Besides, serum non-HDL-C is widely available and inexpensive, suggesting that serum non-HDL-C may be suitable for initial screening high-risk individuals with SSHL in healthcare settings, such as primary healthcare and occupational health institutions.
Nevertheless, some limitations of the present study are worth noting. First, this study was a single-center observational study and only the internal validation was performed; therefore, whether the results could be applied to other regions needs further independent validation. Secondly, although the participants recruited in the present study were matched,[11] several potential confounders may also need to be adjusted, such as audiological factors (hearing loss degree and configuration), brain trauma and noise exposure, as well as lipid-lowering drugs use and smoking status, which were not available from the original data.

5. Conclusions
Our results showed that serum non-HDL-C level positively correlated with increased incidence of SSHL. Moreover, serum non-HDL-C has the potential to be a useful predictor for SSHL, which may help improve early evaluation and management of the risk of SSHL.

Acknowledgments
Authors acknowledge all the participants involved in the study.

Author contributions
Conceptualization: Saibin Wang.

Data curation: Qian Ye.
Formal analysis: Qian Ye.
Funding acquisition: Saibin Wang, Yibin Pan.
Investigation: Saibin Wang.
Methodology: Saibin Wang.
Project administration: Saibin Wang.
Software: Saibin Wang.
Supervision: Yibin Pan.
Writing – original draft: Saibin Wang.
Writing – review & editing: Saibin Wang.

References
[1] Oh JH, Park K, Lee SJ, et al. Bilateral versus unilateral sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2007;136:87–91.
[2] Stachler RJ, Chandrasekhar SS, Archer SM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 2012;146:S1–35.
[3] Aimoni C, Bianchini C, Botin M, et al. Diabetes, cardiovascular risk factors and idiopathic sudden sensorineural hearing loss: a case-control study. Audiol Neurootol 2010;15:111–5.
[4] Cadoni G, Scorpecci A, Canfrone F, et al. Serum fatty acids and cardiovascular risk factors in sudden sensorineural hearing loss: a case-control study. Ann Otol Rhinol Laryngol 2010;119:82–8.
[5] Finger RP, Gostian AO. Idiopathic sudden hearing loss: contradictory clinical evidence, placebo effects and high spontaneous recovery rate—where do we stand in assessing treatment outcomes? Acta Otolaryngol 2006;126:1124–7.
[6] Byl FM Jr. Sudden hearing loss: eight years’ experience and suggested prognostic table. Laryngoscope 1984;94:647–61.
7 Park IS, Kim YB, Choi SH, et al. Clinical analysis of recurrent sudden sensorineural hearing loss. ORL J Otorhinolaryngol Relat Spec 2013;75:245–9.
8 Kim DR, Lee HJ, Kim HJ, et al. Dynamic changes in the inner ear function and vestibular neural pathway related to the progression of labyrinthine infarction in patient with an anterior inferior cerebellar artery infarction. Otol Neurotol 2011;32:1596–9.
9 Chau JK, Lin JR, Atashband S, et al. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope 2010;120:1011–21.
10 Ballesteros F, Alobid I, Tassies D, et al. Is there an overlap between sudden neurosensorial hearing loss and cardiovascular risk factors? Audiol Neurootol 2009;14:139–45.
11 Lee JS, Kim DH, Lee HJ, et al. Lipid profiles and obesity as potential risk factors of sudden sensorineural hearing loss. PLoS One 2015;10: e0122496.
12 Yavuz E, Morawski K, Telischi FF, et al. Simultaneous measurement of electrocochleography and cochlear blood flow during cochlear hypoxia in rabbits. J Neurosci Methods 2003;147:55–64.
13 Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report. J Clin Lipidol 2014;8:29–60.
14 Wang S, Zhang J, Lu X. Non-linear association of plasma level of high-density lipoprotein cholesterol with endobronchial biopsy bleeding in patients with lung cancer. Lipids Health Dis 2019;18:17.
15 Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486–97.
16 Robinson JG. Are you targeting non-high-density lipoprotein cholesterol? J Am Coll Cardiol 2009;53:42–4.
17 Lauer MS, Fontanarosa PB. Updated guidelines for cholesterol management. JAMA 2001;285:2508–9.
18 Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413–9.
19 de Vries M, Klop B, Castro Cabezas M. The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice—point of view. Atherosclerosis 2014;234:473–5.
20 Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015;350:g7594.
21 Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol 2015;16:e173–80.